Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Moodys
Federal Trade Commission
Mallinckrodt
US Army
Daiichi Sankyo
Cipla
Colorcon
Healthtrust

Generated: May 28, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,030,106

« Back to Dashboard

Which drugs does patent 7,030,106 protect, and when does it expire?

Patent 7,030,106 protects ZETIA and is included in one NDA.

Protection for ZETIA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has two hundred and eleven patent family members in thirty-eight countries.
Summary for Patent: 7,030,106
Title:Sterol absorption inhibitor compositions
Abstract:The present invention provides compositions, therapeutic combinations and methods including: (a) at least one peroxisome proliferator-activated receptor activator; and (b) at least one substituted azetidinone or substituted .beta.-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols.
Inventor(s): Cho; Wing-Kee Philip (Princeton, NJ)
Assignee: Schering Corporation (Kenilworth, NJ)
Application Number:10/136,968
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,030,106
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 7,030,106

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Msd Intl Gmbh ZETIA ezetimibe TABLET;ORAL 021445-001 Oct 25, 2002 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,030,106

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,056,906 Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women ➤ Sign Up
6,982,251 Substituted 2-azetidinones useful as hypocholesterolemic agents ➤ Sign Up
7,071,181 Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors ➤ Sign Up
7,053,080 Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Cantor Fitzgerald
UBS
Federal Trade Commission
Teva
Fish and Richardson
Chubb
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.